Roche licenses drug to target cancer DNA damage response
Outsourcing Pharma
JULY 18, 2023
Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.
Let's personalize your content